Apr 16, 2008 - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) announced that data from pharmacokinetic studies of PX-12 and preclinical studies of PX-866 were presented at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, held April 12-16, 2008. Information from the studies may guide future clinical development plans for these product candidates. Oncothyreon is currently conducting a Phase 2 trial of PX-12 in patients with advanced pancreatic cancer and PX-866 is expected to enter a Phase 1 trial in patients with advanced cancers in the second quarter of 2008... Oncothyreon's Press Release -
May 6, 2008
Oncothyreon's PX-12 and PX-866 Data presented at AACR Annual Meeting
Apr 16, 2008 - Oncothyreon Inc. (Nasdaq: ONTY) (TSX:ONY) announced that data from pharmacokinetic studies of PX-12 and preclinical studies of PX-866 were presented at the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, held April 12-16, 2008. Information from the studies may guide future clinical development plans for these product candidates. Oncothyreon is currently conducting a Phase 2 trial of PX-12 in patients with advanced pancreatic cancer and PX-866 is expected to enter a Phase 1 trial in patients with advanced cancers in the second quarter of 2008... Oncothyreon's Press Release -
